Richard P Baum1, Andreas Kluge2, Franz Josef Gildehaus3, Marcus Bronzel2, Karl Schmidt2, Christiane Schuchardt1, Stephan Senftleben1, Samuel Samnick4. 1. Department of Nuclear Medicine/PET Centre, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437 Bad Berka, Germany. 2. ABX-CRO Advanced Pharmaceutical Services, Forschungsgesellschaft m.b.H, 01307 Dresden, Germany. 3. Department of Nuclear Medicine, Laboratory of Radiopharmaceutical Chemistry, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany. 4. Department of Nuclear Medicine, Experimental Nuclear Medicine and Radiopharmacy, University of Würzburg, 97080 Würzburg, Germany.
Abstract
PURPOSE: To explore feasibility, tolerability, dosimetry and probable efficacy of intravenous endoradiotherapy with carrier-added 4-[(131)I]iodo-L-phenylalanine (c.a. (131)I-IPA) in refractory high-grade glioma. METHODS: Two male patients (45 and 50 years), with long-standing, extensively pre-treated gliomas and evidence of progression underwent single intravenous injections of 2 and 4 GBq of c.a. (131)I-IPA, respectively. Tumour targeting was verified by (131)I-IPA single-photon emission computed tomography (SPECT). Metabolic and morphological changes indicative of tumour response were assessed by sequential [(18)F]fluoroethyltyrosine ((18)F-FET) positron emission tomography (PET) and contrast-enhanced magnetic resonance imaging (MRI) following therapy. Further monitoring included clinical state, safety laboratory, quality of life and dosimetry. Absorbed mean organ and whole-body doses were determined according to the Medical Internal Radiation Dose (MIRD) scheme using OLINDAEXM based on serial planar scintigraphy. RESULTS: Both patients tolerated the treatment well. No evidence of acute or delayed organ toxicity was observed. (131)I-IPA accumulated in the tumour recurrences identified by MRI/(18)F-FET. In patient 1, PET showed progressively decreasing maximum standardised uptake values (SUVmax) over 10 months, indicating metabolic response, paralleled by reduced contrast enhancement and tumour volume on MRI. Progression occurred 18 months after therapy. Treatment was repeated using 6.6 GBq of (131)I-IPA, to which no response was observed. Patient 2, followed-up for 3 months after therapy, showed stable disease on MRI and PET. Mean absorbed whole body doses ranged from 0.13 to 0.17 mSv/MBq, with the highest absorbed organ doses to kidneys, bladder and heart (0.86-1.23; 0.49-0.6 and 0.45-0.56 mSv/MBq). CONCLUSION: Systemic endoradiotherapy using up to 6.6 GBq of c.a.(131)I-IPA is not associated with clinically detectable toxicity. Measurable anti-tumour effects in gliomas were observed. (131)I-IPA warrants further evaluation as glioma therapy.
PURPOSE: To explore feasibility, tolerability, dosimetry and probable efficacy of intravenous endoradiotherapy with carrier-added 4-[(131)I]iodo-L-phenylalanine (c.a. (131)I-IPA) in refractory high-grade glioma. METHODS: Two male patients (45 and 50 years), with long-standing, extensively pre-treated gliomas and evidence of progression underwent single intravenous injections of 2 and 4 GBq of c.a. (131)I-IPA, respectively. Tumour targeting was verified by (131)I-IPA single-photon emission computed tomography (SPECT). Metabolic and morphological changes indicative of tumour response were assessed by sequential [(18)F]fluoroethyltyrosine ((18)F-FET) positron emission tomography (PET) and contrast-enhanced magnetic resonance imaging (MRI) following therapy. Further monitoring included clinical state, safety laboratory, quality of life and dosimetry. Absorbed mean organ and whole-body doses were determined according to the Medical Internal Radiation Dose (MIRD) scheme using OLINDAEXM based on serial planar scintigraphy. RESULTS: Both patients tolerated the treatment well. No evidence of acute or delayed organ toxicity was observed. (131)I-IPA accumulated in the tumour recurrences identified by MRI/(18)F-FET. In patient 1, PET showed progressively decreasing maximum standardised uptake values (SUVmax) over 10 months, indicating metabolic response, paralleled by reduced contrast enhancement and tumour volume on MRI. Progression occurred 18 months after therapy. Treatment was repeated using 6.6 GBq of (131)I-IPA, to which no response was observed. Patient 2, followed-up for 3 months after therapy, showed stable disease on MRI and PET. Mean absorbed whole body doses ranged from 0.13 to 0.17 mSv/MBq, with the highest absorbed organ doses to kidneys, bladder and heart (0.86-1.23; 0.49-0.6 and 0.45-0.56 mSv/MBq). CONCLUSION: Systemic endoradiotherapy using up to 6.6 GBq of c.a.(131)I-IPA is not associated with clinically detectable toxicity. Measurable anti-tumour effects in gliomas were observed. (131)I-IPA warrants further evaluation as glioma therapy.
Authors: Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Nadja Sell; Andrea Schaefer; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick Journal: Eur J Nucl Med Mol Imaging Date: 2005-05-18 Impact factor: 9.236
Authors: Samuel Samnick; Jochen B Bader; Dirk Hellwig; Jean Richard Moringlane; Christof Alexander; Bernd F M Romeike; Wolfgang Feiden; Carl-Martin Kirsch Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Nasuda Danchaivijitr; Adam D Waldman; Daniel J Tozer; Christopher E Benton; Gisele Brasil Caseiras; Paul S Tofts; Jeremy H Rees; H Rolf Jäger Journal: Radiology Date: 2008-04 Impact factor: 11.105
Authors: Samuel Samnick; Bernd F Romeike; Thomas Lehmann; Ina Israel; Christian Rübe; Angelika Mautes; Christoph Reiners; Carl-Martin Kirsch Journal: J Nucl Med Date: 2009-11-12 Impact factor: 10.057